Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Nan, Chen,; Jiaqi, Qian,; Jianghua, Chen,; Xueqing, Yu,; Changlin, Mei,; Chuanming, Hao,; Gengru, Jiang,; Hongli, Lin,; Xinzhou, Zhang,; Li, Zuo,; Qiang, He,; Ping, Fu,; Xuemei, Li,; Dalvin, Ni,; Stefan, Hemmerich,; Cameron, Liu,; Lynda, Szczech,; Anatole, Besarab,; Thomas B, Neff,; Yu, Kin-Hung, Peony; Frank H, Valone,

doi:10.1093/ndt/gfx011

Public

Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.

Published in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • Aug 1, 2017

Authors:

Chen, Nan

Qian, Jiaqi

Chen, Jianghua

Abstract

BACKGROUND: FG-4592 (roxadustat) is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (HIF-PHI) promoting coordinated erythropoiesis through the transcription factor HIF. Two Phase 2 studies were conducted in China to explore the safety and efficacy of FG-4592 (USAN name: roxadusta...

Subject

FG-4592

anemia in chronic kidney disease

erythropoiesis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!